Education
About Us
Working with TipRanks
Follow Us
Olympus Corp. (JP:7733)
:7733
7733 Stock Chart & Stats
¥1993.50
¥60.50(2.58%)
At close: 4:00 PM EST
¥1993.50
¥60.50(2.58%)
Day’s Range― - ―
52-Week Range¥1,352.50 - ¥2,168.00
Previous CloseN/A
Volume4.23M
Average Volume (3M)3.67M
Market Cap
¥1.49T
Enterprise Value¥1.57T
Total Cash (Recent Filing)¥196.74B
Total Debt (Recent Filing)¥237.82B
Price to Earnings (P/E)38.6
Beta0.75
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.01%
Share Statistics
EPS (TTM)12.87
Shares Outstanding1,114,485,700
10 Day Avg. Volume4,971,740
30 Day Avg. Volume3,665,053
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)2.96
Price to Sales (P/S)2.23
P/FCF Ratio15.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)62.14
Revenue Forecast (FY)¥996.38B
Bulls Say, Bears Say
Bulls Say
High MarginsOlympus’s high gross (~67%) and operating (~15%) margins indicate durable pricing power and an efficient cost structure in its endoscopy franchise. Those margins support sustained R&D and product refresh cycles, provide a cushion vs procedure-volume swings, and underpin medium-term earnings resilience.
Improving Balance SheetLeverage has materially improved (TTM D/E ~0.32 vs near ~0.90 historically) while equity remains sizable and ROE is healthy. Lower leverage increases financial flexibility for targeted M&A, capex and share actions, reduces refinancing risk, and strengthens balance-sheet resilience over the medium term.
Recurring Consumables & ServiceOlympus’s installed endoscope base drives recurring sales of consumables, single‑use devices and service contracts. These annuity-like, high-margin streams create customer lock-in, smooth revenue volatility tied to procedure volumes, and support predictable cash generation over months to years.
Bears Say
Stalled Top-lineTTM revenue being roughly flat signals limited organic growth momentum. Without revenue expansion, Olympus must rely on margin improvements, product refresh cycles or service expansion to lift profits, constraining medium-term upside and making growth more execution-sensitive.
Variable Free Cash FlowFree cash flow has been uneven: FCF roughly half of net income in TTM and a swing from negative FCF in FY2024 to a rebound in FY2025. That variability reduces predictability for dividends, buybacks and sustained R&D or M&A, complicating long-term capital allocation decisions.
Profitability VolatilityReported margins and net income have shown significant swings, with an unusually high net margin in FY2024 that normalized thereafter. Such earnings volatility can materially change returns and leverage metrics, making forecasting harder and increasing execution risk for strategic plans.
Olympus News
7733 FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was ¥1352.50 and its highest was ¥2168.00 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is ¥1.49T.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is Aug 12, 2026 which is in 157 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on Feb 13, 2026. The company reported ¥12.87 earnings per share for the quarter, missing the consensus estimate of ¥23.057 by -¥10.187.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Overvalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.01%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of ¥12.87 in its last earnings report, missing expectations of ¥23.057. Following the earnings report the stock price went down -5.219%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in JP:7733
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
7733 Company Deck
7733 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong financial performance with significant revenue and profit growth, particularly in North America. However, the resignation of the CEO amid allegations and challenges in China and other markets posed notable concerns. The overall sentiment is balanced by robust operational achievements and strategic advancements, such as AI medical device approvals.View all JP:7733 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---